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Abstract
Cancer immunotherapy has greatly advanced in recent years. Most immunotherapeutic strategies are based on the use of 
immune checkpoint blockade to unleash antitumor immune responses or on the induction or adoptive transfer of immune 
effector cells. We aim to develop therapeutic vaccines based on recombinant Semliki Forest virus vectors to induce tumor-
specific effector immune cells. In this review, we describe our ongoing work on SFV-based vaccines targeted against human 
papillomavirus- and hepatitis C virus-related infections and malignancies, focusing on design, delivery, combination strate-
gies, preclinical efficacy and product development for a first-in-man clinical trial with an HPV-specific vaccine.
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Abbreviations
Ad  Adenovirus
APC  Antigen-presenting cell
CIN  Cervical intraepithelial neoplasia
CTL  Cytotoxic T lymphocyte
CTLA-4  Cytotoxic T lymphocyte antigen-4
DREP  DNA replicon
ER  Endoplasmic reticulum
GITR  Glucocorticoid-induced TNFR-related protein
GMP  Good manufacturing practice
HCV  Hepatitis C virus
HPV  Human papillomavirus
HSIL  High-grade squamous intraepithelial lesion
IP  Infectious particles
MDSC  Myeloid-derived suppressor cell
nsPs  Non-structural proteins
PBMC  Peripheral blood mononuclear cell
PD-1  Programmed cell death protein-1
PRR  Pattern recognition receptor
rSFV  Recombinant SFV
SFV  Semliki Forest virus
SIN  Sindbis virus
Treg  Regulatory T cell
VEE  Venezuelan equine encephalitis virus
VRP  Virus-like replicon particles
Introduction
Immunotherapy, which was recognized as the breakthrough 
of the year 2013, has given a new direction to the develop-
ment of anti-cancer therapies. Cancer immunotherapies aim 
to stimulate or unleash the patient’s immune system to attack 
cancers. These strategies are primarily based on antibodies 
targeting immune checkpoints, tumor-specific antibodies, 
a diversity of adoptive cell therapies, therapeutic vaccines 
and immunomodulators [1, 2]. Therapeutic vaccines include 
synthetic peptides, recombinant proteins, nucleic acids, 
autologous cells and bacterial or recombinant viral vectors. 
Recombinant viral vector vaccination is attractive above all 
others as it generally offers high infection efficiency, antigen 
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expression and immunogenicity. Vector-based vaccines have 
been generated from a diversity of viruses including adeno-
viruses, adeno-associated virus, vaccinia viruses, poxviruses 
and alphaviruses [2]. Our work in recent years has focused 
on developing therapeutic cancer vaccines based on Semliki 
Forest virus (SFV) replicon particles for the treatment of 
human papillomavirus (HPV)- and hepatitis C virus (HCV)-
related infections/malignancies.
This review aims to summarize the development of our 
SFV-based cancer vaccines. We will describe the various 
preclinical evaluation studies conducted in our lab, which 
ultimately led to the first-in-man trial of an SFV-based vac-
cine in 2017.
The Semliki Forest virus replicon vector 
system
The most frequently used alphavirus vectors are derived 
from SFV [3], Venezuelan Equine Encephalitis virus (VEE) 
[4] and Sindbis virus (SIN) [5]. Alphaviruses are enveloped 
viruses containing a positive strand RNA genome of about 
11–12 kb, coding for the non-structural replicase and the 
structural proteins. The genomic RNA has a methylated 
nucleotide cap at the 5′-terminus and a polyadenylated tail 
at the 3′-terminus, resembling cellular mRNA. Alphaviruses 
form spherical enveloped particles (65–70 nm diameter) 
with their genome contained within an icosahedral capsid. 
The envelope contains two major glycoproteins, E1 and E2, 
forming heterologous spikes that act as attachment proteins. 
After virus attachment and entry into the cell, gene expres-
sion and replication take place within the cytoplasm [6, 7].
The SFV-based replicon vector system was first devel-
oped by Peter Liljeström and Henrik Garoff at the Karo-
linska Institute, Stockholm [3]. Additional SFV-based 
vectors were developed with improved biosafety [8, 9]. 
The recombinant SFV (rSFV) vector RNA codes for the 
viral replicase while the sequence encoding the structural 
proteins of SFV can be replaced by a gene of interest. The 
recombinant virus particles called replicons, due to their 
self-replicating nature, are obtained by co-transfection of 
cells with the vector RNA and the helper RNA encoding 
the structural proteins [10]. As the helper RNA does not 
express the replicase, amplification of both the vector and 
the helper RNAs is driven by the replicase of the vector 
RNA. The capsid protein recognizes the packaging sig-
nal located in the replicase region of the vector RNA and 
packs only the recombinant vector RNA into nucleocap-
sids. The envelope/spike proteins migrate to the plasma 
membrane where they interact with nucleocapsids leading 
to the formation and subsequent budding of virus repli-
con particles (Fig. 1). Since SFV vectors are engineered 
such that the replicon particles lack sequences coding for 
the viral structural proteins, they are capable of only one 
round of infection and replication. SFV RNA does not 
integrate into the host genome and since infection with 
SFV induces apoptosis, this minimizes the risk of con-
stitutive expression of heterologous proteins (antigen of 
interest). For clinical translation, increased biosafety is 
required to further reduce the risk of recombination of 
the two RNAs that could lead to the formation of replica-
tion-competent virus. For this, Smerdou and Liljeström 
developed the so-called two-helper system in which the 
structural genes coding for the spike and capsid proteins 
are placed on two separate helper RNA constructs [9].
Following immunization, rSFV particles infect a broad 
range of cells that undergo apoptosis. Thereafter, apoptotic 
bodies containing antigen are taken up by antigen-pre-
senting cells (APCs) which can then present to  CD8+ and 
 CD4+ T cells leading to the generation of antigen-specific 
cellular immune responses. A major difference between 
VEE and SFV replicon particles is that VEE replicon par-
ticles preferentially target dendritic cells resulting in direct 
MHC class I presentation of the antigen, whereas SFV 
replicon particles cannot translate their RNA in APCs but 
induce CTL response via cross-priming [11, 12]. Infection 
with SFV and other alphaviruses leads to the formation 
of double-stranded RNA (dsRNA) intermediates, which 
are recognized as “danger signals” by pattern recognition 
receptors such as RIG-I and trigger production of type I 
interferons [13, 14]. Therefore, recombinant vector vac-
cines based on alphaviruses are capable of activating both 
the innate and the adaptive arms of the immune system.
Another type of SFV-based vector that Liljestrӧm and 
colleagues developed is the DNA replicon (DREP) [15]. 
This vector system combines the advantages of the SFV 
replicon vector with that of a DNA vaccine, which are 
ease of production and cost-effectiveness. The plasmid 
contains cDNA sequences of the SFV replicase, where the 
transcription of the viral replicon is under the control of 
a CMV promoter and where the mRNA coding for the for-
eign antigens is expressed from an internal viral promoter 
on the replicon RNA. Upon transfection with DREP plas-
mid DNA, the DNA is transported to the nucleus where 
the RNA polymerase drives its transcription to RNA. The 
recombinant mRNA transcript is then transported to the 
cytoplasm, where the translation of the SFV replicase 
directs replication and high production of the foreign pro-
tein in a way similar to that by SFV replicons [10].
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Preclinical evaluation of SFV‑based replicon 
vaccines
Therapeutic HPV vaccine rSFVeE6,7
HPV infection is associated with over 99% cases of cervical 
cancer, the fourth most common cancer type among women 
worldwide [16, 17]. HPV infection is also a causal agent of 
other genital cancers such as penile, vaginal, vulvar and anal 
but also an increasing percentage of oropharyngeal cancers. 
The high-risk HPV types 16 and 18 are the most common 
and are associated with approximately 70% of cervical can-
cer cases. In general, the virus is cleared but if the infection 
persists, low- to high-grade cervical intraepithelial neoplasia 
(CIN) and ultimately cervical carcinoma may develop. 
Malignant transformation of epithelial cells is accomplished 
through integration of HPV viral DNA genome into the host 
genome with the disruption of genes including E2, a nega-
tive regulator of the HPV oncoproteins E6 and E7. High 
expression of these oncoproteins in transformed cells is 
responsible for the induction and maintenance of cellular 
transformation.
Currently, there are three prophylactic HPV vaccines 
available: Cervarix, Gardasil and Gardasil-9 [18]. These 
vaccines effectively induce HPV type-specific antibodies to 
prevent the most prevalent high-risk HPV infections. Despite 
the availability of these highly effective prophylactic HPV 
vaccines, over 85% of young adolescent females worldwide 
transcription
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Fig. 1  Production of antigen of interest by SFV replicon. Infection 
with rSFVeE6,7 results in introduction of vector RNA directly in the 
cytoplasm. Thereafter, the RNA translates the SFV replicase which 
drives the transcription/amplification of replicon RNA. Translation 
of large amounts of subgenomic RNA results in production of the 
encoded fusion protein. Upon delivery of DREPeE6,7 into the cell, 
DNA is transported to the nucleus where transcription of the repli-
con takes place following which produced RNA is exported to the 
cytoplasm followed by the same replication and translation process as 
described above for rSFVeE6,7
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are not vaccinated [19], either because an HPV vaccine is 
not provided in a national vaccination program in many low- 
or middle-income countries or because of fear of side-effects 
or opposition to vaccination.
In patients with (pre)malignant cervical cancer, cellular 
and humoral responses are observed, but they are not suf-
ficient to eliminate HPV-transformed cells [20]. A thera-
peutic vaccine that is able to induce strong cellular immune 
response against HPV-transformed cells is therefore highly 
desirable. Since the viral oncoproteins E6 and E7 of HPV 
are constitutively expressed in transformed cells, they serve 
as ideal targets for immunotherapy against HPV-induced 
lesions or malignancies. We first generated an SFV vec-
tor expressing the E6 and E7 protein of HPV16 as separate 
proteins, rSFVE6E7. The replicon particle vaccine based 
on this vector induced moderate immune responses in a 
murine model of cervical cancer with TC-1 tumors [21]. 
To enhance this response, we inserted the first 34 amino 
acid residues of the capsid gene of SFV, which functions 
as a translational enhancer [22], in front of the gene coding 
for a fusion protein of E6 and E7. Thus, a recombinant SFV 
vector expressing high levels of a stable fusion protein of 
HPV16 E6 and E7 was generated, termed rSFVeE6,7 [23]. 
We demonstrated that rSFVeE6,7 replicon particles could 
induce more potent anti-tumor responses than the initial 
vaccine rSFVE6E7, leading to the complete eradication of 
established TC-1 tumors. Furthermore, tumor rechallenge 
studies demonstrated long-term protection. When previously 
immunized mice were rechallenged with tumor cells after 3 
or 6 months, the mice were still protected from tumor out-
growth without another round of immunization and high lev-
els of CTL activity could be measured even up to 11 months 
after immunization [23, 24]. rSFVeE6,7 vaccination could 
also break immune tolerance in HPV16-transgenic mice 
[25].
Various immunotherapeutic approaches use viral vector-
based systems for immunization against tumors. The adeno-
virus (Ad) system is one of the most widely used viral vector 
system, which has also been extensively studied in human 
trials [26–29]. We therefore compared the efficacy of a 
recombinant replication-defective Ad (rAd) vaccine express-
ing the fusion protein of E6 and E7 with the rSFVeE6,7 vac-
cine. We found that prime-boosting with rSFVeE6,7 resulted 
in higher CTL activity and anti-tumor activity compared to 
that with rAdeE6,7, even with 100- to 1000-fold lower doses 
compared to the adenoviral vector [30]. Part of this result 
can be ascribed to the fact that the low dose of rSFVeE6,7 
required to induce an optimal immune response (< 106 infec-
tious particles), generated relatively low levels of SFV-neu-
tralizing antibodies that did not prohibit the responsiveness 
to a booster immunization. The levels of neutralizing anti-
bodies elicited upon rAdeE6,7 immunization however com-
pletely blocked antigen expression and a booster response. 
Vector-specific immunity against adenoviral vectors are 
extensively studied and strategies are being developed to 
reduce anti-Ad immunity to improve their efficacy as gene 
delivery system [31, 32].
Therapeutic hepatitis C virus vaccines
Hepatitis C virus (HCV) is a human tumor-associated virus 
that is transmitted by blood and mainly infects the liver. The 
majority of hepatitis C virus-infected patients (> 70%) do 
not clear the infection naturally and develop chronic hepa-
titis, which is associated with the development of liver cir-
rhosis, liver failure and hepatocellular carcinoma [33]. The 
standard-of-care treatment for HCV infection in developed 
countries is based on a combination of very effective antivi-
ral drugs. Although these drugs are highly potent, they are 
very expensive, may induce resistance and are not widely 
available. It is also important to note that antiviral treatments 
aim only at inhibiting HCV replication, but not at induc-
ing HCV-specific T-cell responses and protective immunity, 
which has been reported to be crucial for the eradication of 
HCV-infected cells.
In patients with chronic HCV infection, a poor and nar-
row-spectrum cellular immune response against HCV is 
often observed while in patients who recovered from acute 
infection, the immune responses are broader. Thus, boost-
ing the host’s immune response against multiple antigenic 
epitopes would theoretically be a valid strategy to eradicate 
persisting viruses and halt associated liver diseases. In the 
context of hepatitis C virus (HCV) infection, the non-struc-
tural proteins (nsPs) of HCV, which are considered to be 
immunogenic and genetically conserved, are identified as 
promising targets for vaccine development. With a view to 
broaden the spectrum of T-cell responses [34], a transgene 
coding the entire non-structural region of HCV could allow 
for responses against subdominant epitopes as well, contrib-
uting to a wider T-cell repertoire [35].
We therefore explored the possibility of expressing the 
HCV nsPs in the rSFV vector to promote the generation of 
HCV-specific and broad-spectrum T-cell responses. Incor-
poration of the major part of the nsPs of HCV, as large as 
6.1 kb, did not affect the immunogenicity of the vaccine. 
We showed that rSFV vectors expressing HCV NS3/4A 
(rSFVeNS3/4A) or all nsPs of HCV (rSFVeNS2′-5B′) 
were capable of inducing strong NS3-specific  CD8+ T-cell 
responses, although the response was slightly lower with 
rSFVeNS2′-5B′ [36]. Both vectors induced polyfunctional 
 CD8+ T cells, exhibited HCV-specific cytolytic activity both 
in vitro as well as in vivo and induced delay in tumor growth.
Taken together, preclinical evaluation of replication-
deficient rSFV vectors demonstrated the ability to induce 
strong effector and memory CTL responses in immuno-
competent as well as immune-tolerant mice and to eradicate 
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pre-established HPV-transformed tumors and HCV-infected 
cells.
Anti‑vector responses
As previously mentioned, immunization with replicon 
viral particles may induce vector-specific immunity, which 
in turn could influence the efficacy of subsequent booster 
immunizations. We investigated the effect of vector-specific 
immune responses on transgene expression and CTL activa-
tion by rSFV. We demonstrated that passively transferred 
SFV-neutralizing antibodies did not prohibit transgene-
specific CTL responses, despite the fact that the transgene 
expression was reduced, albeit not to the level observed with 
adenoviral booster injections [30, 37]. On the other hand, 
priming with irrelevant rSFV reduced transgene expression 
upon subsequent administration of rSFV and inhibited CTL 
induction due to vector-specific responses, which could be 
reversed with the co-administration of a relevant antigen 
(E7-virosomes) at priming. Incorporating an E7-protein 
antigen along with irrelevant rSFV and then boosting with 
rSFVeE6,7, induced a similar percentage of E7-specific 
CTLs as prime-boost immunization with rSFVeE6,7. This 
points towards a possible role of T-cell competition as a 
mechanism by which vector-specific immunity interferes 
with transgene-specific CTL induction. This study con-
firmed that virus-neutralizing antibodies or vector-specific 
CTLs do not prohibit the boosting efficacy of rSFV in 
homologous prime-boost immunizations and rather T-cell 
competition has a stimulatory effect in such regimens [37]. 
Yet, SFV-based vaccines have also been successfully used 
in heterologous combinations with other vaccines [38–42].
Antigen design
As the immunogenicity of rSFV relies on cross-priming, 
the protein of interest should not be (completely) degraded 
before being processed by antigen-presenting cells. As 
described above, expression of a more stable fusion protein 
of E6 and E7 induced higher immune responses compared 
to the vaccine expressing the E6 and E7 proteins separately 
[21, 23, 24]. With the aim of further improving the effi-
cacy of our vaccine, we assessed the potential of the repli-
con particles expressing the HPV16 E6,7 fusion protein or 
E7SH (a shuffled version of the E7 protein) coupled with 
helper T-cell epitopes and an ER targeting signal (sigHELP-
KDEL), a strategy which successfully improved the efficacy 
of DNA vaccines [43, 44]. Immunization with both rSFVe-
sigHELP-E6,7-KDEL and rSFVe-sigHELP-E7SH-KDEL 
augmented E7-specific T-cell responses as compared to 
the corresponding parent vectors. A suboptimal dose of 
rSFVe-sigHELP-E6,7-KDEL significantly enhanced the 
anti-tumor responses compared to rSFVeE6,7. Strong mem-
ory responses were generated providing protective immunity 
to the mice against formation of TC-1 tumors.
Inclusion of helper T epitopes and an ER targeting signal 
further increased the immunogenicity of our HPV vaccines, 
which was likely due to enhanced protein stability and ren-
dered therapeutic as well as prophylactic immunity with a 
suboptimal dose of the vaccine [45].
Delivery routes and methods
The route of immunization influences vaccine efficacy. We 
demonstrated that subcutaneous (s.c.) injection of the vector 
vaccine elicits potent CTL and anti-tumor responses [24]. 
We further explored different routes of immunization to 
determine their influence on the degree of vaccine-induced 
immune response. We demonstrated that these responses 
were strongly augmented with i.v. (intravenous) and i.m. 
(intra-muscular) administrations. Although CTL activity 
was induced upon i.p. (intraperitoneal) and s.c. immuniza-
tions, i.v. and i.m. induced much higher CTL frequencies. 
We also compared i.m. vs i.v. immunization with two sub-
optimal treatment regimens and concluded that both i.m. 
and i.v. administrations are equally effective in generating 
anti-tumor responses [46].
Besides the above-mentioned delivery routes, we exam-
ined intra-dermal delivery by means of tattooing. The skin, 
being rich in APCs, such as Langerhans cells and dermal 
dendritic cells, is an attractive site for immunization. Tat-
tooing has been mostly described for DNA- and peptide-
based vaccines [47–50]. We compared tattoo delivery vs 
intra-muscular administration of rSFVeE6,7 and found that 
despite having a tenfold lower overall transgene expression 
(injection site and draining lymph nodes), tattooing induced 
similar levels of immune responses in comparison with i.m. 
delivery of the replicon particles [51]. This delivery method 
resulted in potent therapeutic anti-tumor response and stimu-
lated long-lasting memory T cells, establishing high immu-
nostimulatory potential of intra-dermal delivery with regard 
to recombinant SFV vector vaccines.
Following on this route, we generated an HPV16 E6,7 
vaccine based on the DREP vector as described above [15] 
and compared it with a conventional DNA vaccine [52]. The 
DNA vaccines were administered intra-dermally followed 
by in vivo electroporation [53, 54] resulting in strong anti-
tumor effects with the DREP vaccine when compared with 
the conventional DNA vaccine pVAX. Upon administra-
tion of equimolar doses of DREP and pVAX, we found that 
DREP strongly enhanced the expression of the protein and 
high percentages of E7-specific  CD8+ T cells were induced, 
which rendered effective anti-tumor immunity compared to 
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pVAX. Remarkably, even with a dose 1000-fold lower than 
that of the conventional DNA vaccine, potent anti-tumor 
efficacy was observed [52]. On the whole, intra-dermal 
delivery of DREP along with electroporation as a method 
of augmenting its efficacy could be a promising alternative 
of vaccine administration for favorable clinical outcome.
Combination strategies
Tumors adopt various mechanisms to evade the immune 
system such as immune-suppressive cells, upregulation of 
inhibitory signals such as PD-1 [55], CTLA-4 [56], etc. 
Therefore, it would be beneficial to target these mechanisms 
to avert their influence on anti-tumor immunity and improve 
the suppressive tumor microenvironment. With the purpose 
of enhancing the efficacy of therapeutic immunization with 
rSFVeE6,7, the next step was to combine the vaccine with 
strategies that can modulate the tumor environment.
We investigated two immune-suppressive cell popula-
tions, regulatory T cells (Tregs) and myeloid-derived sup-
pressor cells (MDSCs). In patients with cervical intraepi-
thelial neoplasia (CIN) and cervical cancer, increased 
frequencies and immunosuppressive activity of Tregs were 
observed [57]. Furthermore, therapeutic immunization 
with different vaccines has been shown to increase num-
bers of Tregs [58, 59]. In the TC-1 model, we observed that 
rSFVeE6,7 immunization neither led to Treg expansion nor 
did it affect Treg activity. Additionally, Treg depletion did 
not enhance the efficacy of the vaccine, implying that in 
this model, the presence of Tregs has no influence on rSFV-
induced immune responses [60].
Radiation therapy using ionizing radiation is a standard 
treatment for many types of cancer, used most frequently 
in combination with surgery or chemotherapy. Local tumor 
irradiation results in the release of tumor antigens and upreg-
ulation of MHC I/II, cytokines and chemokines involved in 
recruitment of T cells to the tumor [61–63]. With an aim to 
increase T cell homing into the tumor, we combined local 
tumor irradiation with the rSFVeE6,7 vaccine. In the mouse 
model, local low-dose tumor irradiation indeed increased 
homing of antigen-specific  CD8+ T cells into tumors. When 
tumor-bearing mice were immunized 1 day following irra-
diation, this effect was further amplified as compared to irra-
diation or immunization alone. Concurrently however, irra-
diation also increased the number of intratumoral MDSCs. 
Since immunization with rSFV did not further increase the 
number of MDSCs, the ratio of antigen-specific  CD8+ T 
cells to MDSCs in tumors increased 85-fold as compared 
to the control. The mRNA expression levels of chemokines 
and their corresponding ligands, such as CCR2 and CCL2, 
CXCR6 and CCL16, were up-regulated upon irradiation 
which most likely attributed to homing of different immune 
cell populations to the tumor. On the whole, this treatment 
regimen led to a strong increase in the ratio of immune effec-
tor cells to immune-suppressive cells, thus skewing towards 
a more anti-tumor microenvironment [64].
Accumulation of MDSCs in lymphoid organs and tumors 
is associated with several pathological conditions such as 
cancer, inflammation and chronic infection [65]. MDSCs are 
potent suppressors of T-cell responses and to overcome their 
immune-suppressive activity, we utilized a receptor tyros-
ine kinase inhibitor, sunitinib malate, due to its capacity to 
selectively deplete MDSCs and block tumor angiogenesis 
[66]. We first tested the effect of sunitinib on the levels of 
MDSCs and observed a dose-dependent decrease in tumor, 
spleen and circulating blood [67]. Concurrently, sunitinib 
dose-dependently increased both intratumoral as well as 
intrasplenic  CD8+ T cells accompanied with enhanced acti-
vation. This was further enhanced on combined treatment of 
sunitinib with rSFV immunization compared to either treat-
ment alone. The ratio of E7-specific  CD8+ T cells to MDSCs 
increased 12.5-fold in comparison with immunization alone 
and enhanced tumor regression [67]. These results suggest 
that this combination therapy could be further investigated 
as a promising approach to improve clinical outcome.
The next step was to combine the above-mentioned strate-
gies, uniting the benefits of single low-dose local tumor irra-
diation with the therapeutic recombinant SFV-based cancer 
vaccine and sunitinib [68]. The triple treatment induced the 
most potent MDSC depletion compared to sunitinib alone. 
Synchronously, the triple treatment caused an increase in 
activated and degranulating intratumoral  CD8+ T cells and 
further boosted E7-specific  CD8+ T cells. The triple treat-
ment strongly enhanced the ratio of E7-specific  CD8+ T cells 
to MDSCs in tumors with a striking 10,000-fold increase 
compared to the control tumors. Altogether, the trimodal 
treatment was successful in blocking tumor development, 
subsequently leading to 100% tumor-free survival of tumor-
bearing mice [68]. The results from this study further 
strengthen the rationale of employing different treatment 
modalities to refine cancer immunotherapeutic approaches 
and bring them closer to the clinic.
With the advent of immune checkpoint blockade, the 
use of monoclonal antibodies targeting several checkpoint 
molecules such as PD-1 and CTLA-4, has garnered much 
interest in cancer immunotherapy. Rice et al. demonstrated 
that immunotherapy with an adenoviral vector vaccine, 
encoding the HPV16 E6 and E7 genes, in combination 
with PD-1 checkpoint inhibition resulted in delayed tumor 
growth and a significant improvement in survival com-
pared to the controls [69]. Another study by Mkrtichyan 
and colleagues showed that PD-1 blockade synergizes 
with depletion of Tregs by low-dose cyclophosphamide 
in enhancing the therapeutic efficacy of the HPV16 peptide 
vaccine [70]. A more recent strategy is the dual approach 
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of targeting both inhibitory as well stimulatory molecules. 
The triple combination of targeting GITR, PD-1 blockade 
and peptide vaccine induced complete regression in half of 
the mice, substantially enhancing the anti-tumor immunity 
[71]. Taking cue from such studies, it would be interest-
ing to investigate the anti-tumor potency of this kind of 
combination therapy with our vaccine.
Product and process development
Promising results from our preclinical studies motivated us 
to test this vaccine in a first-in-man phase I clinical trial. 
The clinical grade Vvax001 was produced at the Unit Bio-
tech and ATMPs of the Department of Clinical Pharmacy 
and Pharmacology, University Medical Center Groningen. 
For application in the trial, the major concern was the scal-
able production of a clinical batch of rSFVeE6,7, which we 
named Vvax001. The production comprised electropora-
tion with three different RNAs, using the two-helper sys-
tem [9] and harvest of the produced viral particles from 
cultures of electroporated cells. This production process 
required optimization with respect to safety, scalability 
and translation to good manufacturing practice (GMP). 
Vero cells, approved for GMP production, were chosen for 
the production of the clinical batch (two-helper system). A 
number of conditions were tested for scalability including 
different electroporation conditions, optimal temperature 
and time for harvesting virus after transfection and per-
centage of fetal bovine serum (FBS). Using the optimized 
protocol, viral titers of the order  108–109 infectious parti-
cles (IP)/ml could be achieved.
A toxicity study was performed in female C57/Bl6 mice 
using a toxicology batch of Vvax001 produced in a process 
that was identical to the production process of the clinical 
grade batch of Vvax001. In addition, tissue distribution and 
persistence was assessed following a single intra-muscular 
administration of the highest dose to be tested in subjects, 
i.e., 5 × 108 IP. No adverse effects were observed in any of 
the treated animals for the parameters examined. All the 
immunized mice had HPV16 E7-specific  CD8+ T cells. Bio-
distribution/persistence study revealed that the majority of 
the Vvax001 RNA expressing E6 and E7 of HPV16 was 
localized at the injection site and was detectable until day 
10, which was thereafter rapidly cleared from all tissues. 
Immunogenicity of the clinical batch with respect to CTL 
induction and anti-tumor responses was comparable to that 
of the rSFVeE6,7 vaccine used previously for all preclinical 
studies. This ‘preclinical’ vaccine was produced on baby 
hamster kidney cells (BHK-21) using the one-helper system. 
Altogether, the toxicity and immunization studies attested 
that the clinical grade Vvax001 was ready for use in the trial.
Clinical trial
Several clinical trials with VEE-based vaccines have 
been conducted [72–74], whereas SFV- and SIN-based 
vector vaccines are yet to be tested in clinic. For exam-
ple, encouraging results were obtained from a phase I/II 
clinical trial, conducted to evaluate the safety and CEA-
specific immune responses to the immunizations with a 
VEE replicon particle vaccine, CEA(6D)-VRP (AVX701), 
in patients with advanced cancer. Repeated administration 
of the vaccine induced clinically relevant CEA-specific 
T cell and antibody responses, despite the generation of 
neutralizing antibodies against the VRP and high levels of 
Tregs in PBMCs. In addition, patients with CEA-specific 
T-cell responses appeared to have better survival. Clini-
cal response observed in some patients was attributed to 
higher dose of VRP-CEA [75].
With respect to HPV, several types of immunothera-
peutic approaches aimed at inducing robust cell-mediated 
responses against HPV-driven infections and malignancies 
have been developed and tested for safety and efficacy in 
clinical trials. A phase II randomized, placebo-controlled 
clinical trial of VGX-3100, a synthetic DNA vaccine tar-
geting HPV 16 and 18 E6 and E7 proteins, in women with 
CIN2/3 resulted in significantly higher histopathological 
regression and viral clearance following VGX-3100 vac-
cination as compared to placebo [76]. This vaccine is cur-
rently being investigated in a phase III trial in women with 
high-grade squamous intraepithelial lesion (HSIL). Ther-
apeutic vaccination with HPV-16 synthetic long peptide 
vaccine in women with vulvar intraepithelial neoplasia 
led to durable complete response in 47% of patients [77]. 
While this vaccine was tested in patients with advanced 
or recurrent HPV-16 positive gynecological carcinoma, 
no clinical benefit was observed despite generation of 
vaccine-induced HPV-16-specific T-cell responses [78]. 
Furthermore, adoptive T cell transfer of HPV-targeted 
tumor-infiltrating T cells in women with metastatic cervi-
cal cancer resulted in responses in three of nine patients 
with one partial and two complete responses [79].
Several types of therapeutics examined in trials have 
rendered varying levels of clinical benefit, which further 
declines in advanced carcinomas. Owing to several advan-
tages of alphaviral vector vaccine platforms and in view 
of remarkable preclinical results, we initiated the first-in-
human trial of Vvax001 in January 2017. The principal 
aim of the trial is to evaluate the safety and side-effects 
as well as immunological activity induced by Vvax001, a 
therapeutic viral vector vaccine encoding a fusion protein 
of HPV16-derived E6 and E7 oncogenes. In this phase I 
study, four dose levels were tested, with three subjects 
per dose level. The study participants received three doses 
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of the vaccine via intra-muscular injection in an interval 
of 3 weeks. The side-effects of the vaccine were scored 
using common toxicity criteria grades. In order to moni-
tor the immune responses, blood was collected at base-
line as well as 7–10 days after second and third vacci-
nations. The immune responses induced by the vaccine 
were assessed in circulating blood following isolation 
of peripheral blood mononuclear cells (PBMCs). HPV-
16-specific responses to vaccination are being evaluated by 
a set of immune monitoring assays including interferon-γ 
ELISPOT (Enzyme-linked ImmunoSpot), intra-cellular 
cytokine staining (ICS), phenotypic staining as well as 
proliferation assay for cell-mediated responses and ELISA 
(enzyme-linked immunosorbent assay) using serum to test 
for antibodies against the viral vector. The results of this 
first-in-human trial with a recombinant SFV replicon vac-
cine will be presented in the second half of 2018.
Conclusions and perspectives
Alphavirus-based vector systems have several advantages: 
(1) high heterologous gene expression; (2) induction of 
apoptosis resulting in cross-presentation of antigens; (3) 
induction of innate and adaptive immune responses and (4) 
lack of pre-existing immunity. The combination of all of 
these features in this vector system results in potent immune 
responses. We have developed therapeutic vaccines based on 
SFV vectors. These vaccines have been specially designed, 
taking into consideration their biosafety for use in humans. 
Immunization with rSFV induces potent anti-tumor immu-
nity and long-term immune memory in mouse tumor mod-
els. The first-in-man trial of Vvax001 will give us further 
information on its safety, tolerability and immunogenicity 
in human subjects. On successful completion of the Phase 
I trial, we would like to evaluate the clinical efficacy of the 
vaccine with respect to regression of lesions in a Phase II 
trial. Based on knowledge of its tolerability and therapeutic 
efficacy in such clinical studies, this vaccine can be extended 
as a platform to other cancer types.
Combining different therapeutic strategies has emerged 
as a promising approach towards enhancing anti-tumor effi-
cacy of cancer immunotherapy. Both radiation therapy and 
sunitinib and their combination can enhance the efficacy of 
cancer vaccines by modifying the tumor microenvironment 
supporting tumor eradication. The next approach would be 
to explore targeted therapies to combine with therapeutic 
vaccination. This approach will focus on the use of mono-
clonal antibodies blocking inhibitory checkpoint molecules 
and/or stimulating co-stimulatory molecules. Comprehen-
sive studies would have to be conducted to attain combina-
tion strategies that have a synergistic effect in preclinical 
models that could be extended to further strengthen anti-
tumor efficacy in clinical studies.
In conclusion, we demonstrated that recombinant SFV 
vectors serve as a suitable vector system for antigen deliv-
ery and the vector vaccines that we have developed provide 
a safe therapeutic tool to combat HCV- and HPV-related 
infections/malignancies.
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